⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director
globenewswire.com
BMY
NVS
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
RAPT
SANG
INCY
ABBV
ARCT
AMGN
CHKP
PFE
LLY
SCLX
SNY
UCB
BIIB
NVS
VTRS
BMY
ABSI
ALEC
GSK
IONS
CLNN
ANNX
MED
GAM
VRTX
EXC
BLRX
TransCelerate Receives DIA Global Inspire Award and Showcases Collaborative Innovation at DIA 2026
prnewswire.com
NVS
GILD
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
globenewswire.com
LYFT
NVS
LLY
RARE
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
globenewswire.com
NVS
How earning a Rutgers Executive MBA motivated an engineer to expand her career ambitions
prnewswire.com
NVS
IgE Receptor Antagonists Clinical Trial Pipeline Analysis: 12+ Key Companies Shaping the Future of IgE Receptor Antagonists Therapeutics | DelveInsight
globenewswire.com
AMRX
ARX
GSK
AZN
SNY
NVS
MRK
REGN
JNJ
PFE
BMY
LLY
VRTX
AMGN
ABBV
GILD
BIIB
CSL
AQST
RAPT
ALGT
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight
globenewswire.com
IMVT
ROIV
MRK
NVS
REGN
UCB
JNJ
ARGX
AMGN
VIR
IPHA
ARWR
APLS
CABA
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
globenewswire.com
NVS